Provenge Should Be "Very Familiar" To CMS Now, Dendreon Says About NCA
Executive Summary
Dendreon has already provided the Centers for Medicare and Medicaid Services with extensive information on its new prostate cancer vaccine Provenge (sipuleucel-T), so a lengthy Medicare national coverage analysis is not needed, the firm maintained in July 27 comments to the agency
You may also be interested in...
CMS Decision To Conduct Provenge NCA Could Be "Chilling To Future Innovation," BIO's Greenwood Says
BIO CEO Jim Greenwood discusses his views on the Medicare national coverage analysis for Dendreon's prostate cancer immunotherapy Provenge with "The Pink Sheet" DAILY.
Provenge Off-Label Use Is Key CMS Concern In NCA, Dendreon Says
In its ongoing national coverage analysis of Dendreon's Provenge (sipuleucel-T), the Centers for Medicare and Medicaid Services is taking a close look at Medicare coverage for off-label use of the novel prostate cancer vaccine, according to the company
Provenge Off-Label Use Is Key CMS Concern In NCA, Dendreon Says
In its ongoing national coverage analysis of Dendreon's Provenge (sipuleucel-T), the Centers for Medicare and Medicaid Services is taking a close look at Medicare coverage for off-label use of the novel prostate cancer vaccine, according to the company